# Balancing Immunity: GSK-3’s Divergent Roles in Dendritic Cell-Mediated T-Cell Priming and Memory Responses

## TL;DR

This paper explores how GSK-3β in dendritic cells both boosts initial T-cell activation and hinders long-term memory T-cell formation, with implications for vaccines and cancer treatments.

## Contribution

The study reveals β-catenin-independent dual roles of GSK-3β in dendritic cells, challenging prior assumptions about its immunomodulatory effects.

## Key findings

- GSK-3β enhances dendritic cell-mediated cross-priming of CD8 T cells.
- GSK-3β impairs the generation of memory CD8 T cells.
- These findings suggest new strategies to optimize immunotherapies by modulating GSK-3 activity.

## Abstract

Glycogen synthase kinase-3 (GSK-3)—particularly the GSK-3β isoform—plays a pivotal role in regulating dendritic cell (DC) functions, including maturation, cytokine production, and antigen presentation. In immature DCs, GSK-3β is continuously active, and its inhibition has been shown to enhance DC maturation and function. As a key upstream kinase of β-catenin, GSK-3 inhibition activates β-catenin in both human and murine DCs—a pathway traditionally linked to its immunomodulatory effects. However, our recent findings challenge this paradigm by uncovering β-catenin-independent, dual roles of GSK-3β in DCs. Our study reveals that while GSK-3β enhances DC-mediated cross-priming of CD8 T cells, it concurrently impairs the generation of memory CD8 T cells. These findings have significant implications for vaccine development and cancer immunotherapy, where both effective T-cell priming and durable memory responses are critical. This mini-review provides an in-depth analysis of mechanistic insights into GSK-3β’s paradoxical functions and discusses potential strategies to fine-tune GSK-3 activity for optimized immunotherapeutic outcomes.